Island Pharma welcomes green light for ISLA-101 clinical study | News Direct

Island Pharma welcomes green light for ISLA-101 clinical study

Island Pharmaceuticals Ltd
News release by Island Pharmaceuticals Ltd

facebook icon linkedin icon twitter icon pinterest icon email icon Melbourne, Victoria | November 07, 2023 10:50 AM Eastern Standard Time

Island Pharmaceuticals Ltd (ASX:ILA) CEO Dr David Foster tells Proactive the company has been granted human research ethics approval to commence its ISLA-101 Single Ascending Dose study. The aim of the study is to ensure that administered doses can safely achieve blood concentrations of ISLA-101 that are predicted to be effective against the dengue virus. Recruitment and dosing will commence imminently, with the data read out expected in early 2024.

“This new patent adds to the growing intellectual property thicket that is being established around ISLA-101,” Foster said.

“This Australian patent, together with the equivalent patents granted in other key markets, underpin the investment we are making in bringing forward ISLA-101 as a potential new approach to combating the world’s growing problem with dengue fever and other mosquito-borne viral diseases.”



Contact Details


Proactive Investors


Jonathan Jackson


+61 413 713 744

project media


Island Pharmaceuticals LtdPharmaAsxproactiveAustraliaproactiveInvestors